Miravirsen - Roche

Drug Profile

Miravirsen - Roche

Alternative Names: Liver-specific microRNA-122 antagonist - Roche; LNA-antimiR™-122; miR-122 antagonist - Roche; Miravirsen sodium; SPC-3649

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Santaris Pharma
  • Developer Roche
  • Class Antivirals; Oligonucleotides; RNA
  • Mechanism of Action MIRN122 microRNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hepatitis C

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hepatitis-C(In volunteers) in Denmark (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hepatitis-C(In volunteers) in Netherlands (IV, Infusion)
  • 03 May 2017 Roche completes an extension trial in Hepatitis C (Treatment-experienced) in USA and Puerto Rico (NCT02452814)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top